REDUCE-IT

URI: https://gptkb.org/entity/REDUCE-IT

GPTKB entity

Statements (104)

Predicate	Object
gptkbp:instanceOf	gptkb:clinical_trial
gptkbp:controls	placebo
gptkbp:country	gptkb:Albania gptkb:Algeria gptkb:Argentina gptkb:Armenia gptkb:Australia gptkb:Austria gptkb:Azerbaijan gptkb:Bahrain gptkb:Bangladesh gptkb:Belarus gptkb:Belgium gptkb:Bosnia_and_Herzegovina gptkb:Brazil gptkb:Bulgaria gptkb:Canada gptkb:Chile gptkb:China gptkb:Colombia gptkb:Croatia gptkb:Cyprus gptkb:Czech_Republic gptkb:Denmark gptkb:Egypt gptkb:Estonia gptkb:Finland gptkb:France gptkb:Georgia gptkb:Germany gptkb:Greece gptkb:Hong_Kong gptkb:Hungary gptkb:Iceland gptkb:India gptkb:Indonesia gptkb:Ireland gptkb:Israel gptkb:Italy gptkb:Japan gptkb:Jordan gptkb:Kazakhstan gptkb:Kuwait gptkb:Latvia gptkb:Lebanon gptkb:Lithuania gptkb:Luxembourg gptkb:Macedonia gptkb:Malaysia gptkb:Malta gptkb:Mexico gptkb:Moldova gptkb:Montenegro gptkb:Morocco gptkb:Nepal gptkb:Netherlands gptkb:New_Zealand gptkb:Norway gptkb:Oman gptkb:Pakistan gptkb:Peru gptkb:Philippines gptkb:Poland gptkb:Portugal gptkb:Qatar gptkb:Romania gptkb:Russia gptkb:Saudi_Arabia gptkb:Serbia gptkb:Singapore gptkb:Slovakia gptkb:Slovenia gptkb:South_Africa gptkb:South_Korea gptkb:Spain gptkb:Sri_Lanka gptkb:Sweden gptkb:Switzerland gptkb:Taiwan gptkb:Thailand gptkb:Tunisia gptkb:Turkey gptkb:Ukraine gptkb:United_Arab_Emirates gptkb:United_Kingdom gptkb:United_States gptkb:Uzbekistan gptkb:Vietnam
gptkbp:endDate	2018
gptkbp:foundIn	icosapent ethyl significantly reduced risk of cardiovascular events
gptkbp:fullName	Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
https://www.w3.org/2000/01/rdf-schema#label	REDUCE-IT
gptkbp:includes	patients with elevated triglycerides and established cardiovascular disease or diabetes plus risk factors
gptkbp:participants	8179
gptkbp:principalInvestigator	gptkb:Deepak_L._Bhatt
gptkbp:publicationYear	2019
gptkbp:publishedIn	gptkb:New_England_Journal_of_Medicine
gptkbp:result	major adverse cardiovascular events
gptkbp:sponsor	Amarin Pharma
gptkbp:startYear	2011
gptkbp:studiedDrug	gptkb:icosapent_ethyl
gptkbp:studyType	gptkb:clinical_trial
gptkbp:bfsParent	gptkb:Vascepa
gptkbp:bfsLayer	8